RIAMTERENE (2,4,7-triamino-6-phenylpteridine) is the first of a relatively new class of diuretics to become available for clinical investigation and therapeutic use. It has been demonstrated to be an antagonist of mineralocorticoids in addition to having a direct diuretic effect in adrenalectomized animals and humans.1-7 Administration of triamterene increases the urinary excretion of sodium, chloride, and water but not of potassium. Early studies indicated that triamterene is able to block the increase in potassium excretion produced by other diuretic agents. This agent has also been reported to have an antihypertensive effect.
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This study had two phases. In phase 1 the antihypertensive effects, electrolyte effects, and side effects of triamterene were compared with those of chlorothiazide and of a placebo. In phase 2 the same effects of combined administration of triamterene and hydrochlorothiazide were compared with those of administration of hydrochlorothiazide alone.
Method Patients
Twenty-one (17 women and 4 men) white adult ambulatory patients were selected for phase 1, and 16 (15 women and 1 man) were selected for phase 2. Thirteen patients participated in both phases. Each patient had clinically verified chronic and sustained hypertension not secondary to a known cause; each had an average blood pressure exceeding 160 mm Hg systolic and 90 mm Hg diastolic during a 6to 8-week period of observation without treatment immediately prior to each study. The severity of hypertension was graded group 1 or group 2 by the Keith-Wagener-Barker classification; none of the patients had 524 McGuCKIN, Ph.D. increased concentration of blood urea, congestive heart failure, or symptomatic cerebrovascular disease. Protocol During each period of study the patients were seen at weekly intervals by one of the investigators. At each visit, after the patient had rested for at least 5 minutes, the lowest two of three measurements of blood pressure when the patient was sitting, the blood pressure when the patient was standing, the pulse rate, the body weight, and observations regarding side effects were recorded. Fasting blood samples were obtained biweekly for determinations of the concentrations of serum sodium, potassium, and uric acid, plasma chloride, and blood urea and glucose. The carbon dioxide-combining power also was determined. The hemoglobin concentration, total and differential leukocyte counts, and serum amylase, alkaline phosphatase, and glutamic-oxaloacetic transaminase (SGOT) activities were determined and urinalysis was done prior to the study and after each 2-month period of drug or placebo administration.
The study was carried out by the double-blind technique. The active medication and the placebo were dispensed under code numbers in a sequence determined by a person not participating in the study. Each dose of medication was administered at 12-hour intervals. During phase 1 of the study, the medication and doses were triamterene (100 mg), chlorothiazide (500 mg), or a placebo, each for 2 months. In phase 2, they received a combination capsule of triamterene (100 mg) and hydrochlorothiazide (50 mg) or hydrochlorothiazide (50 mg) alone, each for 2 months. No other antihypertensive agents were administered during the study periods. Results
Phase 1
As summarized in table 1, triamterene alone caused a slight decrease in average systolic blood pressure, but less than that noted during treatment with chlorothiazide when compared to placebo. Average diastolic blood pressures Circulation, Volume XXXIV, September 1966 From the Mayo Clinic and Mayo Foundation, Rochester, Minnesota. were not changed by triameterene but were decreased by chlorothiazide. The average blood pressure response for each patient is shown in table 2. Mean changes in pulse rate and mean body weight are shown in table 1. The mean concentration of serum potassium increased by 0.3 mEq/liter during treatment with triamterene but decreased by 0.4 mEq/ liter with chlorothiazide, as compared with the placebo value. These changes were statis- No significant changes were found in blood hemoglobin concentration, total and differential leukocyte counts, or serum transaminase, alkaline phosphatase, and amylase activities except for those in the one patient who was not continued on the study for reasons noted below.
One patient (case 10) was withdrawn from the study at the end of the fourth week on the triamterene regimen because of side effects and abnormal results of blood tests. During the first 3 days of the regimen she had noted transient lightheadedness which cleared. On day 20 she was confined to bed because of malaise, nausea, vomiting, and diarrhea, as were others with whom she lived. Her symptoms were alleviated only slightly by an antacid preparation and persisted after the other members of the family were well. The patient remained confined to bed because of nausea, flatulence, and malaise. Her weight decreased from 117 to 111 pounds. Triamterene therapy was stopped on day 28; she noted improvement within 1 week and subsequently regained weight to 121 pounds. Results of laboratory tests done on this patient are shown in 
.) 
C7, N m g/ 100 ml of blood) without evident blood loss, an increase in the blood concentration of urea, and an increase in serum glutamicoxaloacetic transaminase activity. After treatment with triamterene was stopped, all laboratory results returned to base line levels. This patient has remained in good health subsequently. There was circumstantial evidence to suggest that triamterene was the cause of the increase in serum glutamic-oxaloacetic transaminase activity and the decrease in hemoglobin concentration. However, there is no proof of this because we chose not to challenge her with another course of triamterene. The laboratory tests obtained did not reveal the cause of the decrease in hemoglobin. Although gastrointestinal loss of blood was not noted by the patient or detected by one stool guaiac test, it could not be positively excluded. There was no history of previous gastrointestinal loss of blood. Phase 2 The changes in blood pressure, pulse, weight, and blood constituents are shown in tables 5 and 6. Systolic blood pressure was reduced minimally during combined therapy without any difference in diastolic blood pres-sures between the two treatments. Pulse rate increased slightly without any change in mean body weight during combined therapy. Changes noted in the blood electrolytes were similar to those noted in phase 1 of this study. The most important change was the increased serum potassium concentration during the combined therapy as compared with the hydrochlorothiazide treatment.
In one patient, serum glutamic-oxaloacetic transaminase (SGOT) activity increased from 0.79 to 2.68 micromoles per hour per milliliter of serum* after combined therapy, and the erythrocyte sedimentation rate increased from 31 to 41 mm in 1 hour (Westergren). The treatment was discontinued, and further tests were performed 1 week later. Sulfobromophthalein (BSP) retention was 22% in 1 hour, but the serum bilirubin concentration and the serum alkaline phosphatase activity remained normal. BSP retention decreased to 6, 8, 10, and 0% on subsequent examinations during the next 3 months. The SGOT also returned to normal within 3 months. The only *Normal value in this laboratory: less than 1.43 micromoles per hour per milliliter of serum. other change noted during combined therapy was a decreased hemoglobin concentration in four patients: by 3 g/ 100 ml of blood in one patient, by 1.5 g in one, and by 1.3 g in two. The hemoglobin concentration returned to normal after treatment was stopped in each instance. There was no comparable decrease of hemoglobin during hydrochlorothiazide therapy.
Side Effects
A summary of the side effects noted during the treatments with triamterene, chlorothiazide, and placebo is shown in table 7. Because of side effects, dosage was temporarily reduced 50% in one patient taking triamterene, three patients taking placebo, and two patients taking chlorothiazide. Nausea accompanied by mild epigastric pain was a complaint of three patients for short periods while they were taking triamterene. Side effects noted during phase 2 were nausea, fatigue, dry mouth, weakness, muscle cramps, and postural dizziness (table 8). In many patients these symptoms only occurred during the first week of therapy and then subsided. It was postulated that this was caused in part by abrupt but transient hypovolemia that followed the initial diuresis. Five patents had no side effects during combined therapy, and 10 patients had no side effects during treatment wvith hydrochlorothiazide alone.
Comment
Triamterene alone was not consistently effective as an antihypertensive agent in either phase of the present study. Four patients taking triamterene had decreases of systolic pressure of 16 to 25 mm Hg and four others had decreases of 11 to 15 mm Hg, but the mean of systolic blood pressures of all of the patients who took triamterene alone was reduced only 7 mm Hg below that during the placebo administration. Five patients had a decrease in diastolic blood pressure of 6 to 10 mm Hg, but nine patients had slight increases in diastolic blood pressures during triamterene therapy. The mean diastolic blood pressure did not change below that noted during the placebo period. In contrast, mean blood pressures were decreased by chlorothiazide by 18 mm Hg systolic and 7 mm Hg diastolic as compared to the mean values during treatment with placebo.
The most impressive finding of this study was the change in the serum potassium concentration during triamterene or combined triamterene-hydrochlorothiazide therapy compared to treatment with a thiazide alone. A significant decrease in the mean serum potassium values was noted during administration of chlorothiazide or hydrochlorothiazide. During triamterene therapy, when used alone as well as when used in combination with hydrochlorothiazide, the mean serum potassium values showed a significant increase when compared with control values. Heath and Freis' demonstrated that, although triamterene was less effective than hydrochlorothiazide as a naturetic agent in nonedematous patients, a combination of 25 mg of hydrochlorothiazide and 50 mg of triamterene produced slightly more naturesis than did 50 mg of hydrochlorothiazide alone. Furthermore, the combination caused slightly less urinary excretion of potassium than during the control Circulation, Volume XXXIV, September 1966 Side Effects Noted Table 7 During Administration of Placebo, Triamterene, or Chlorothiazide period whereas 50 mg of hydrochlorothiazide alone caused a considerably greater potassium loss in the urine than was noted during the control period. Previous animal and human studies'-7 have indicated that triamterene has both antialdosterone-like activity and a direct renal tubular diuretic action promoting naturesis and blocking kaluresis. When triamterene is used alone, changes in levels of urea, uric acid, and sugar in the blood seem to parallel those seen with chlorothiazide. When hydrochlorothiazide is combined with triamterene, the increase in concentration of urea, uric acid, and sugar appears to be additive.
Circulation, Volume XXXIV, September 1966 Side effects noted during triamterene therapy were similar in type and frequency to those noted during thiazide therapy. This study suggests in addition a possible relationship between triamterene and abnormal liver function and between triamterene and a decreased hemoglobin concentration in some patients. Although we were unable to prove a relationship between triamterene and the changes in BSP retention, SGOT activity, and hemoglobin values, no other conditions were present to account for the changes. All of the abnormal values returned to normal within 3 months after triamterene therapy was discontinued. We have not seen mention of similar changes in liver function or hemoglobin values in previously reported experiences with triamterene. As triamterene may become an important and frequently used agent in the treatment of edematous patients, if not in nonedematous hypertensive patients, such parameters should be monitored and side effects should be studied in an attempt to determine the cause.
This study offers evidence that triamterene may be a useful adjunct for certain thiazidetreated hypertensive patients by decreasing the likelihood of complicating hypokalemia. Summary Triamterene (2,4,7-triamino-6-phenylpteridine) was employed alone and in combina-tion with hydrochlorothiazide in the treatment of patients with group 1 and 2 hypertension. In 21 patients, triamterene alone had an inconsistent antihypertensive effect on the systolic blood pressure, which was minimal in most patients. In 16 patients the combination of triamterene and hydrochlorothiazide (2:1 by weight) reduced the systolic blood pressure slightly more than did hydrochlorothiazide alone. Triamterene alone or in combination with hydrochlorothiazide produced an increase in the concentration of potassium in serum. Side effects due to triamterene were similar to those noted with thiazide diuretics. In addition, five patients had a decrease Circulation, Volume XXXIV, September 1966 in blood hemoglobin concentration, and two patients had reversible alterations in liver function during triamterene therapy. Triamterene may be a useful adjunct for thiazidetreated hypertensive patients by decreasing the likelihood of complicating hypokalemia.
